Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 163

The DOI matches its Crossref record.

A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS

Open access
Fenaux, Pierre, Santini, Valeria, Spiriti, Maria Antonietta Aloe, Giagounidis, Aristoteles, Schlag, Rudolf, Radinoff, Atanas, Gercheva-Kyuchukova, Liana, Anagnostopoulos, Achilles, Oliva, Esther Natalie, Symeonidis, Argiris, Berger, Mathilde Hunault, Götze, Katharina S., Potamianou, Anna, Haralampiev, Hari, Wapenaar, Robert, Milionis, Iordanis, Platzbecker, Uwe·2018·Leukemia

Abstract

Erythropoiesis-stimulating agents are first choice for treating anemia in low-risk MDS. This double-blind, placebo-controlled study assessed the efficacy and safety of epoetin-α in IPSS low- or intermediate-1 risk (i.e., low-risk) MDS patients with Hb ≤ 10.0 g/dL, with no or moderate RBC transfusion dependence (≤4 RBC units/8 weeks). Patients were randomized, 2:1, to receive epoetin-α 450 IU/kg/week or placebo for 24 weeks, followed by treatment extension in responders. The primary endpoint was erythroid response (ER) through Week 24. Dose adjustments were driven by weekly Hb-levels and included increases, and dose reductions/discontinuation if Hb > 12 g/dL. An independent Response Review Committee (RRC) blindly reviewed all responses, applying IWG-2006 criteria but also considering dose adjustments, drug interruptions and longer periods of observation.A total of 130 patients were randomized (85 to epoetin-α and 45 to placebo). The ER by IWG-2006 criteria was 31.8% for epoetin-α vs 4.4% for placebo (p < 0.001); after RRC review, the ER was 45.9 vs 4.4% (p < 0.001), respectively. Epoetin-α reduced RBC transfusions and increased the time-to-first-transfusion compared with placebo.Thus, epoetin-α significantly improved anemia outcomes in low-risk MDS. IWG-2006 criteria for ER may require amendments to better apply to clinical studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41375-018-0118-9

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 163

Metadata

Authors
Fenaux, P., Santini, V., Spiriti, M. A. A., Giagounidis, A., Schlag, R., Radinoff, A., Gercheva-Kyuchukova, L., Anagnostopoulos, A., Oliva, E. N., Symeonidis, A., Berger, M. H., Götze, K. S., Potamianou, A., Haralampiev, H., Wapenaar, R., Milionis, I., & Platzbecker, U.
Venue
Leukemia
Published
2018-03-30
Volume
32
Issue
12
Pages
2648-2658
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2794499016
Cited by
163
References
0
FWCI
10.03
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. https://app.cochat.ai/papers/10.1038/s41375-018-0118-9
The paper
Fenaux, P., Santini, V., Spiriti, M. A. A., Giagounidis, A., Schlag, R., Radinoff, A., Gercheva-Kyuchukova, L., Anagnostopoulos, A., Oliva, E. N., Symeonidis, A., Berger, M. H., Götze, K. S., Potamianou, A., Haralampiev, H., Wapenaar, R., Milionis, I., & Platzbecker, U. (2018). A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. Leukemia. https://doi.org/10.1038/s41375-018-0118-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.